Biopharma | Medical Device, Digital Health and Diagnosis

Harvest Pharmaceuticals

Founded in December, 2011, Harvest Pharmaceuticals is a research and development enterprise for high tech drugs, focusing on high-end generic drugs and innovative drugs. The company concentrates on the development of drug technologies, making it its mission to develop drugs which can improve the life quality of human beings. The company has 110 employees (including 102 R&D technicians), while most of them have years of experience in European and U.S. drug development and registration. The company is a high-tech enterprise recognized by the Torch Center of the Ministry of Science and Technology, the first batch of small and technological innovation giants in Changsha, the “Gazelle Enterprise” in Changsha High-tech Zone and one of the national-level science and technology small and medium-sized enterprises.

Needs & Requirements

The company would like to introduce high-end drug delivery technology and use the new technology to develop new pharmaceutical dosage forms and and delivery methods, For example, speed-controlled release formulations, such as rapid release formulations and slow-release formulations, and directional controlled release formulations, such as microspheres, targeted emulsions, magnetic drug formulations, liposomes, and macromolecular drug delivery systems, to provide high-level support to establish and improve high-end formulation technology platforms.

Hunan Huacheng Biotech, Inc.


Founded in 2008 and with a registered capital of ¥725.95933 million, Hunan Huacheng Biotech Inc is a national high-tech enterprise specializing in the planting, research and development, production, sales and service of natural sweetener extraction, separation and purification products. It is currently the biggest national level high-tech enterprise in natural sweetener purification and scale production. Its competitive product Mogroside has a large market potential for its high saftey, high-sweetness, zero calorie and wide range of biological activity. The company has invented frequency conversion separation technology, agricultural residues removal technology, organic membrane separation technology, supercritical fluid extraction, bio-fermentation technology and so on, making great achievements and breakthroughs in the research, development and industrial production of natural sweeteners including Mogroside. The company has applied for 74 invention patents, including 23 invention patents, and has applied 5 PCT and 30 trademarks (“Huacheng Green Branch” is a famous trademark in Hunan).

Needs & Requirements

In response to the increasing global status of obesity and diabetes, the company would like to establish a R&D center to carry out its application research in the food field, developing 5-10 popular products with low calorie and good taste; Conduct global sales of monkfruit fructose and terminal application products and get demands for joint ventures by founding sales companies.

Hunan Jiudian Pharmaceutical Co.,Ltd.

Established in January 2001, with registered capital of ¥234.68 million and total assets of ¥940 million, Hunan Jiudian Pharmaceutical Co.,Ltd. is an integrated, tech-drivien enterprise of scientific research, production and sales, with all-round business in preparations, APIs, pharmaceutical excipients and plant extracts. At present, there are more than 900 employees, with 200 of them in the Jiudian Pharmaceutical Research Institute, accounting for more than 20% of the total number of employees. The company’s main business ranges from pharmaceutical, raw materials, pharmaceutical recipients, plant extracts, food research and development, production, sales, and related product technology research and development, consultation and technology transfer. In 2018, the company achieved sales income of ¥820.79 million and a profit of ¥80.36 million.

Needs & Requirements

The company wishes to collabotate with U.S. companies in the following aspects:
1. introduce advanced formula technology from U.S., and improve the clinical “superiority” of drugs during the process of researching innovative drugs, expand anti-infective, cardiovascular and cerebrovascular, antihypertensive and lipid-lowering products, develop and produce new high-end preparations which are adapted to the Chinese market and even international market (especially European and U.S.)
2. During the imitation study of long-acting preparations with high-tech content slow release agents and microspheres, the company hopes to solve the problem related to the nature, excipients and production process of the preparations and drugs during research by direct introduction or cooperative development of new drug delivery systems.
3. As one of the fastest growing sub-sectors in the pharmaceutical industry in recent years, biopharmaceuticals hopes to introduce innovative biopharmaceuticals through the introduction of advanced biotechnology in U.S. due to its technology-intensive characteristics and current technical bottlenecks in the entire domestic industry. To solve the lack of biopharmaceuticals in the domestic pharmaceutical market, reduce the production cost of biopharmaceuticals, and bring hope to more patients.

Hunan Fangsheng Pharmaceutical Co.,Ltd.

Founded in June 2002, Hunan Fangsheng Pharmaceutical Co.,Ltd. has a workforce of nearly 3,000 people, with a R&D team over 100 people. The health industry group is a high-quality, comprehensive enterprise integrating pharmaceutical industry, medical services and healthy retirement, having a number of subsidiaries. The company was listed on the Shanghai Stock Exchange on December 5, 2014. (Stock code: 603998)

Needs and Requirements

The company has the following needs:
Complex injection projects: complex injection projects with technical barriers and clinical advantages such as liposomes and microspheres can help the company build a complex injection technology platform.

New drug projects with clinical application advantages: it is necessary to find new drug projects that have completed preclinical research into the clinical research stage, and the existing data can prove that there are obvious clinical application advantages.

Generic drug projects with a wide range of clinical needs: foreign companies with sound generic drug research and development systems can consider a variety of cooperation models (joint ventures, production technology transfer, etc.)

Hubei Topgene Biotechnology Co.,Ltd

Hubei Topgene Biotechnology Co.,Ltd is a high-tech pre-clinical CRO enterprise featuring non-human primates, focusing on high-end experimental animal breeding research, high-value non-human primate model development and pre-clinical safety evaluation of biological drug research and development.

JOINTO Technology Co., Ltd.

Founded in 2014 and registered with ¥50 million, JOINTO Technology Co., Ltd. is a high-tech company specializing in R&D, production and sale of ultrasound (fetus-voice meter, fetus monitor meter), laser innovation medical device and medical consumables. The company has 30 employees. There are 13 R&D professionals, making 43% of all. In 2018, the company reached¥20.3422 million sales revenue, paid ¥1.0474 million of tax and invested ¥3.8 million in R&D. The company owns core independent IPR for all the main products and filed 61 application of patents including 39 invention(2 PCT patents), 9 practical new type patents and 13 exterior patents. The company has been authorized with 12 patents including 2 inventions, 2 practical new type patents and 8 exterior patents. Another 2 software copyrights have been registered. In the meanwhile, the company has completed the construction of IP standard system.

Needs & Requirements

The company is in need of technical cooperation in terms of artificial intelligence, mainly about AI identification in ultrasonic imaging, driving mechanical automatic device to move the ultrasound probe to the area of interest. The specific requirement is to distinguish the characteristic points according to ultrasonic images, using prior learning experience to identify the human body scan cross interface corresponding to the current ultrasound image, therefore locating the specific position and angle of the ultrasound probe in the human body, deduce the specific error from the region of interest according to the current position, and then drive the mechanical device to the correct position.

Sansure Biotech Inc.

Sansure Biotech Inc was founded by Dr. Lizhong Dai. Focusing on molecular diagnostic and gene detection, the company is dedicated to providing medical diagnostic reagent and equipment, third-party medical diagnostic services. At present, the company is the benchmark enterprise in the global molecular diagnostic industry, also becomes the first batch of national gene detection technology Application Demonstration Center and the only national infectious diseases and tumor gene diagnosis technology Joint Engineering Research Center. Technical personnel accounted for 40% of employees throughout the company, developing technologies like: the high-precision “Magnetic Bead Method” which won the second prize of national Scientific and Technological Progress, world’s first fast and easy “one-step” technology, the universal “automatic unified sample processing” technology, the world’s fastest “POCT mobile molecular Diagnosis” technology, etc. Winning the second prize of National Science and Technology Progress, China Patent Excellence Award and nearly 20 other national major innovation awards, the company is guiding the industry development towards the direction of high refinement, simplicity, automation, systematization.

Sinocare Inc.

Sinocare Inc. is a high-tech listed company devoted to the whole course management of diabetes. Founded in 2002, headquartered in Changsha, Hunan Province, China, and listed on the Shenzhen Stock Exchange in 2012, it is a national innovation fund project and a national biomedical engineering demonstration project. In 2016, Sinocare acquired Trividia Health, Inc and PTS successfully, becoming the leading company in the global blood glucose meter industry.
At present, Sinocare has reached 58.5% of the national retail market share, and has become the leading enterprise in the industry of blood glucose monitoring products in China. Sinocare is the first and fifth largest manufacturer of blood glucose meters in China’s retail market and around the wo rld respectively with business in 135 countries and regions.
The business performance of Sinocare is healthy and promising. The sales revenue is growing rapidly. In 2018, Sinocare achieved ¥2.6 billion in global business income and the domestic revenue witnessed 29.80% year-on-year growth. The total profit reached ¥305 million and the tax exceeded ¥0.1 billion for three consecutive years.

Hunan Guangxiu Hi-tech Life Technology Co., Ltd.

Hunan Guangxiu Hi-tech Life Technology Co., Ltd. focuses on the research and industrial operation of human stem cells, and specializes in directed differentiation of human embryonic stem cells, islet stem cell transplantation, and development of new scaffold materials for tissue engineering.